Adamas publishes new data analyses demonstrating gocovri treatment more than doubled on time without dyskinesia in patients with parkinson's disease

Emeryville, calif.--(business wire)--adamas pharmaceuticals, inc. (nasdaq: adms), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the publication of an article entitled “amantadine er (gocovri®) significantly increases on time without any dyskinesia: pooled analyses from pivotal studies in parkinson's disease” in the peer-reviewed journal frontiers in neurology. gocovri® (amantadine) extend
ADMS Ratings Summary
ADMS Quant Ranking